←
Schug Lab198 posts
Schug Lab avatar

Schug Lab

@SchugLab

The Schug Lab studies cancer metabolism with a focus on fatty acids. Our favorite fatty acid...acetate! Reach out if you’re interested in joining us!

◷ Joined August 2019
Schug Lab avatar
Schug Lab@SchugLab·May 26

Hi everyone! The Schug Lab is searching for a Lab Manager. If you are interested, please have a look through the job description and apply through the link below. This position is funded through new grant support. jeffersonhealth.wd5.myworkda…

U.S. Surgeon General avatar
⟳ Schug Lab retweeted
U.S. Surgeon General@Surgeon_General·3 Jan 2025

NEW: Today, I’m releasing a Surgeon General’s Advisory on the causal link between alcohol consumption and increased cancer risk. Alcohol is the 3rd leading preventable cause of cancer in the U.S., contributing to about 100,000 cancer cases and 20,000 cancer deaths each year.

Post attachment
Russell Jones avatar
⟳ Schug Lab retweeted
Russell Jones@DrRGJonesLab·13 Dec 2024

Happy to announce our collaboration with @Tcellogic on metabolic features of exhausted T cells is now out in @ScienceMagazine. TL;DR they can't use acetate to fuel their function. Great work by Shixin Ma and Mike Dahabieh. science.org/doi/10.1126/scie…

Katherine Aird avatar
⟳ Schug Lab retweeted
Katherine Aird@airdlab·10 Dec 2024

Our work on metabolism of quiescent cells! A bit of a new area for us in collaboration with the Buckanovich lab

New research reveals that #acetate drives quiescence in ovarian #cancercells by boosting ACSS2-mediated acetyl-CoA production. High ACSS2 levels are linked to poor patient outcomes and #chemoresistance. Targeting ACSS2 could enhance treatment response! 🔗sciencedirect.com/science/ar…

Post attachment
Schug Lab avatar
Schug Lab@SchugLab·25 Nov 2024

Excited to share our latest study on ACSS1 and acetate metabolism in cancer, which was spearheaded by two graduate students in the lab. Stay tuned for more exciting news from the Schug Lab!

ACSS1-dependent acetate utilization rewires mitochondrial metabolism to support AML and melanoma tumor growth and metastasis dlvr.it/TGKcML

Irem:) avatar
⟳ Schug Lab retweeted
Irem:)@kaymakirrm·16 Aug 2024

My baby girl came on Monday night and closing the week with a first author paper from @DrRGJonesLab ! What a week!! Many thanks to everyone for all the efforts to get this paper out!!

Kaymak, Watson @DrRGJonesLab @VAInstitute and colleagues show that production of cytosolic acetyl-CoA by ACLY and ACSS2 links CD8 T cell metabolic state and effector function through effects on #chromatin accessibility. hubs.la/Q02Lzc7r0 #Metabolism #LymphocyteBiology

Post attachment
Delgoffe Lab avatar
⟳ Schug Lab retweeted
Delgoffe Lab@DelgoffeLab·13 Jun 2024

New preprint from the lab is online! The product of a stellar collaboration with @Muir_Lab, we explore a chemically defined physiologic media formulation based of the metabolite of tumor interstitial fluid (TIF, or “tumor juice”) and its effects on T cell function! A brief 🧵1/

Julianna Supplee avatar
⟳ Schug Lab retweeted
Julianna Supplee@JuliannaSupplee·5 Jun 2024

Happy to report that our paper, where we grapple with the mystery of ACLY splice isoforms, is finally out! jbc.org/article/S0021-9258(2… @WellenLab @MarmorsteinLab

Dzmitry Mukha avatar
⟳ Schug Lab retweeted
Dzmitry Mukha@dzmitrybio·1 Jun 2024

🔬 Excited to share @SchugLab’s latest findings at #ASMS2024! Join me at the poster session where we’ll delve into: 1. Targeted Metabolomics. 2. FASN (Fatty Acid Synthase) and fatty acid biosynthesis. 3. Coenzymes A, malonate, and succinate. 4. Mitochondria (should I add ‘powerhouses’?). ➡️ ThP133, Thu, June 6, 10:30 am ⬅️ See you there! 🌟🧪📊 #TeamMassSpec

Post attachment
Russell Jones avatar
⟳ Schug Lab retweeted
Russell Jones@DrRGJonesLab·29 May 2024

Happy to share our new paper in print today in @ScienceAdvances exploring nutrient utilization by CD8 T effector cells in vivo using infusion of 13C tracers. Great work by Eric Ma, Mike Dahabieh and collaborators at @VAInstitute and @AgiosPharma. science.org/doi/10.1126/scia…

Dzmitry Mukha avatar
⟳ Schug Lab retweeted
Dzmitry Mukha@dzmitrybio·6 May 2024

I am excited to share our preprint "Identification of Fasnall as a therapeutically effective Complex I inhibitor." biorxiv.org/content/10.1101/… Several things from inside 👇 We asked a question: What happens with the polar metabolome of cancer cells when fatty acid synthase (FASN) is inhibited? We found that three widely used FASN inhibitors likely do not inhibit FASN in cells. Instead, we reassign one of them, Fasnall, as a new Complex I inhibitor. Fasnall can reach therapeutic concentrations in vivo and effectively prevent tumor growth in several OXPHOS-dependent tumor models (breast cancer xenografts and one model of BRAFi/MEKi double-resistant melanoma PDX). Fasnall joins the set of known Complex I inhibitors, such as rotenone, metformin, mubritinib, and IACS-010759. Unlike the latter, Fasnall seemingly does not cause painful neuropathies in vivo. Mubritinib (TAK-165) was previously known as an ERBB2 inhibitor, and its activity was reassessed in the work by Baccelli et al. (2019). 🧵